Dilated Cardiomyopathy Panel
Use
This test is intended for individuals with relevant features who have a clinical or suspected diagnosis of dilated cardiomyopathy, a condition characterized by the enlargement of the heart's ventricles and impaired contractility. It is also suitable for individuals who have a family member diagnosed with dilated cardiomyopathy but have not undergone genetic testing themselves. Moreover, this test can aid those without access to specific variant information of a family member with genetically-confirmed dilated cardiomyopathy.
Special Instructions
It is important to note that STAT testing is available for expedited processing, which significantly reduces the reporting time. For efficient processing, clients can utilize the myPrevent online ordering system or submit the test requisition form provided in PDF format. Additionally, PreventionGenetics offers the option of targeted family testing as a follow-up to the initial panel results, allowing for refinement of genetic findings within affected families.
Limitations
The test is based on Next-Generation Sequencing (NGS) technologies and has limitations inherent to this methodology, including potential challenges in detecting low-level mosaicism and certain structural variants outside the panel's targeted regions. Copy number variants can be detected over broad regions but might miss small or complex rearrangements. Additionally, the genomic content not specifically targeted by this panel will not be analyzed, which may include regions of relevance in genetic backgrounds not covered by the panel's gene set. Interpretations are also limited by current genetic knowledge and database information, which may not cover all pathogenic variants.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided